Edesa Biotech Secures $15 Million Through Strategic Placement
Edesa Biotech, Inc. (Nasdaq: EDSA) has executed a notable private placement deal, raising $15 million. This financing effort was led by Velan Capital, with an impressive turnout from both new and existing institutional investors who focus on healthcare. Edesa’s initiative is aimed at furthering its innovative work in host-directed therapeutics geared towards treating immuno-inflammatory diseases.
Details of the Fundraising
The company successfully sold 834 Series B-1 convertible preferred shares along with approximately 3.47 million common shares. The pricing for each preferred share was set at $10,000, while the common shares sold for $1.92 each. Remarkably, insiders and officers from the company also participated by purchasing around $1.1 million worth of shares.
Investor Participation
The placement was executed directly, bypassing the need for intermediaries such as placement agents or underwriters. Key new participants in this funding round included renowned firms like Nantahala Capital and Broadfin Holdings LLC, alongside existing shareholders who contributed significantly to this venture.
Utilization of Funds
Edesa intends to allocate the net proceeds from this offering to bolster the advancement of EB06, its promising CXCL10 monoclonal antibody. This funding will specifically support the transition of EB06 into a Phase 2 clinical study targeting individuals suffering from nonsegmental vitiligo, a condition characterized by patches of skin losing color. Additionally, the funds will assist in managing working capital and other general corporate needs.
Strengthening Governance
In a significant move, the company appointed David Liu, a Senior Analyst at Velan Capital, to its Board of Directors following the completion of the offering. This integration reflects the strategic collaboration between Edesa and its investors.
Regulatory Considerations
The private placement is conducted under specific regulatory frameworks, including the Securities Act of 1933 and associated exemptions. The shares offered are allocated to accredited investors, a classification that ensures compliance with Canadian securities regulations. Furthermore, Edesa has committed to filing a registration statement with the Securities and Exchange Commission, aiming for registration of the common shares and conversion shares sold.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. specializes in developing therapeutic solutions that address inflammatory and immune-related conditions. The company’s innovative pipeline covers two main areas: Medical Dermatology and Respiratory Health. In the dermatology sector, their lead candidate, EB06, targets vitiligo, while EB01 is being developed as a treatment for Allergic Contact Dermatitis. Their respiratory portfolio includes EB05, currently under evaluation for treating Acute Respiratory Distress Syndrome, a serious respiratory condition.
Continued Commitment to Innovation
Edesa’s extensive research efforts are complemented by funding initiatives from governmental organizations, underscoring the potential and importance of their drug candidates in the healthcare market. The company is also preparing to file an investigational new drug application for EB07, with an eye towards Phase 2 studies aimed at treating pulmonary fibrosis.
Frequently Asked Questions
What is the total amount raised by Edesa Biotech?
Edesa Biotech raised a total of $15 million through its recent private placement.
Who led the financing round for Edesa’s private placement?
Velan Capital led the financing round with participation from other institutional investors.
What are the funds primarily used for?
The funds are primarily earmarked for advancing Edesa's EB06 program into a Phase 2 clinical study for vitiligo and for working capital purposes.
Are there any regulatory guidelines concerning the shares sold?
Yes, the shares were offered in compliance with the Securities Act of 1933 and specific exemptions, ensuring they are available to accredited investors only.
What is Edesa's primary focus in biopharmaceutical development?
Edesa focuses on creating therapeutics aimed at immuno-inflammatory diseases through innovative drug candidates.
